Blockade of results of smoked cannabis with the CB1-selective cannabinoid receptor antagonist SR141716. Our in vitro effects propose that EAM-2201 need to be examined in terms of potential in vivo pharmacokinetic drug–drug interactions brought on by time-dependent inhibition of CYP2C8, CYP2C9, CYP2C19 and CYP3A4 routines and aggressive inhibition of UGT1A3 https://angelokcqer.blog-ezine.com/31222980/the-best-side-of-eam-2201